These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12573196)

  • 1. Cyclooxygenase-2 inhibitors: is there an association with coronary or renal events?
    Bing RJ
    Curr Atheroscler Rep; 2003 Mar; 5(2):114-7. PubMed ID: 12573196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of cardiovascular events associated with selective COX-2 inhibitors.
    Mukherjee D; Nissen SE; Topol EJ
    JAMA; 2001 Aug 22-29; 286(8):954-9. PubMed ID: 11509060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C; Wagner S
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Renal tolerance of selective inhibitors of cyclooxygenase type 2].
    Deray G
    Presse Med; 2001 Oct; 30(30):1507-12. PubMed ID: 11712212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.
    Whelton A; Maurath CJ; Verburg KM; Geis GS
    Am J Ther; 2000 May; 7(3):159-75. PubMed ID: 11317165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular events and COX-2 inhibitors.
    Fleming M
    JAMA; 2001 Dec; 286(22):2808; author reply 2811-2. PubMed ID: 11735742
    [No Abstract]   [Full Text] [Related]  

  • 9. Does celecoxib use increase the risk of cardiovascular events?
    Oviedo JA; Schroy PC
    Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib.
    White WB; Faich G; Borer JS; Makuch RW
    Am J Cardiol; 2003 Aug; 92(4):411-8. PubMed ID: 12914871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences.
    Stöllberger C; Finsterer J
    South Med J; 2004 Feb; 97(2):209. PubMed ID: 14982279
    [No Abstract]   [Full Text] [Related]  

  • 12. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib-related renal papillary necrosis.
    Akhund L; Quinet RJ; Ishaq S
    Arch Intern Med; 2003 Jan; 163(1):114-5. PubMed ID: 12523925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A side effect of COX-2 inhibitors.
    Harv Health Lett; 2003 Apr; 28(6):7. PubMed ID: 12777233
    [No Abstract]   [Full Text] [Related]  

  • 15. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
    Weaver A; Alderman M; Sperling R
    Am J Cardiol; 2003 May; 91(10):1291-2. PubMed ID: 12745131
    [No Abstract]   [Full Text] [Related]  

  • 16. Arthritis medicines and cardiovascular events--"house of coxibs".
    Topol EJ
    JAMA; 2005 Jan; 293(3):366-8. PubMed ID: 15623849
    [No Abstract]   [Full Text] [Related]  

  • 17. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arthritis. Should you be taking a COX-2 inhibitor?
    Harv Health Lett; 2001 Nov; 27(1):1-3. PubMed ID: 11724695
    [No Abstract]   [Full Text] [Related]  

  • 19. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Celecoxib-induced acute interstitial nephritis.
    Henao J; Hisamuddin I; Nzerue CM; Vasandani G; Hewan-Lowe K
    Am J Kidney Dis; 2002 Jun; 39(6):1313-7. PubMed ID: 12046048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.